US Patent

US11957660 — Edaravone suspension for oral administration

Formulation · Assigned to Mitsubishi Tanabe Pharma Corp · Expires 2039-11-01 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a formulation of edaravone for oral administration as a suspension that includes edaravone particles, a dispersant, and water.

USPTO Abstract

An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Drugs covered by this patent

Patent Metadata

Patent number
US11957660
Jurisdiction
US
Classification
Formulation
Expires
2039-11-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Mitsubishi Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.